SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

EDG-003

EWTX·Edgewise Therapeutics, Inc.
NEUTRAL
Drug Impact Rating1/10
Trial phase
Preclinical / Discovery
Time to market
Unknown, preclinical discovery stage; likely 5+ years from any potential commercialization, if it advances at all.
Why 1/10
EDG-003 is a preclinical discovery-stage program with no clinical trials, no IND filing, no scheduled readout, and no PDUFA date in the next ~12 months. The company's value (~$4.9B market cap) is overwhelmingly driven by EDG-7500 (Phase 2/3 HCM) and the recent $1.55B+ Servier deal, not by this early program.
Actionable Insight NEUTRAL

EDG-003 is too early-stage to move the stock on its own in the next year. Investors should focus on EWTX's real catalysts: the Phase 3 initiation of EDG-7500 in HCM expected Q4 2026 and any milestone payments from the Servier sevasemten sale. EDG-003 is a pipeline filler at the discovery stage, no trading thesis can be built around it.

Price Chart

Loading chart...

Executive Summary

EDG-003 is a preclinical discovery program at Edgewise Therapeutics (NASDAQ: EWTX), not a single clinical-stage drug candidate. It explores novel cardiac modulators for undisclosed cardiometabolic indications. The program has already generated one clinical-stage asset, EDG-7500, now in Phase 2 trials for hypertrophic cardiomyopathy, but no specific EDG-003 candidate has entered human trials. Edgewise recently sold its neuromuscular (sevasemten) program to Servier for up to $2.65B ($1.55B upfront), transforming into a cardiovascular-focused company. EDG-003 represents a long-option, early-stage pipeline program with no near-term binary catalysts.

How It Works

EDG-003 is a discovery program within Edgewise that identifies small-molecule drugs designed to modulate cardiac muscle proteins, aiming to treat cardiometabolic diseases (conditions that involve both heart and metabolic dysfunction). The specific drug candidate(s) in this program and their exact targets have not been publicly disclosed.

Trial Status

EDG-003 is a preclinical discovery program exploring novel small-molecule cardiac modulators for undisclosed cardiometabolic diseases. No IND has been filed, and no clinical trials have been initiated. The program has already produced at least one clinical-stage asset (EDG-7500, now in Phase 2 for hypertrophic cardiomyopathy).

The Two-Sided Case

▲ Bull Case4
Edgewise just completed a $1.55B upfront cash deal with Servier, giving it a strong balance sheet to fund early discovery work like EDG-003 through potential approval of its lead assets.
The EDG-003 discovery program already produced one winner, EDG-7500, now in Phase 2/3 for HCM, suggesting the platform can identify viable drug candidates.
Cardiometabolic disease is a massive market, and if EDG-003 yields a novel therapy, it could open a significant commercial opportunity.
Top-tier institutional holders like RA Capital ($328M position), Baker Bros. ($207M), and BlackRock ($204M) as of Q1 2026 signal informed money sees value in Edgewise's pipeline.
▼ Bear Case5
EDG-003 is at the preclinical discovery stage, no IND filed, no clinical trials, no public data. It's impossible to assess whether any candidate will be viable.
The target indication is undisclosed, meaning investors cannot evaluate the competitive landscape or addressable market for this specific program.
Edgewise's stock is driven almost entirely by EDG-7500 (HCM) catalysts. EDG-003 is immaterial to near-term valuation and won't move the stock.
Discovery-stage biotech programs fail at very high rates, likely 90%+ of preclinical candidates never reach the market.
CSO Alan J. Russell sold $7.9M in stock on July 1, 2026 (via a 10b5-1 plan), which may signal insider view that shares reflect current pipeline value.

Upcoming Catalysts

  • No EDG-003-specific catalysts scheduled. Company catalysts to watch: Phase 3 trial initiation for EDG-7500 in HCM (expected Q4 2026), Phase 2 EDG-15400 HFpEF data, and potential sevasemten milestone payments from Servier upon regulatory milestones.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Edgewise Therapeutics, Inc. 8-K EWTX ·Originating report

Sources · 8

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 gurufocus.com5 biotech-readout.beehiiv.com6 sec.gov7 tipranks.com8 edgewisetx.com